Prenatal Test for Fetal Aneuploidy Detection

NCT01256606 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2013-01-10

No results posted yet for this study

Summary

The purpose of this study is to develop and evaluate a blood test for pregnant women for detection of fetal aneuploidy.

Conditions

  • Aneuploidy
  • Trisomy 21

Sponsors & Collaborators

  • Roche Sequencing Solutions

    lead INDUSTRY

Principal Investigators

  • Ken Song, MD · Ariosa Diagnostics

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256606 on ClinicalTrials.gov